Blog
RSS FeedPosted by Michael Wonder on 10 Jan 2019
2018 in a nutshell: new edition with facts and graphics from the IQWiG
9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...
Posted by Michael Wonder on 17 Dec 2018
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
17 December 2018 - Could reinsures solve problem of high upfront costs of developing potentially life-saving treatments? ...
Posted by Michael Wonder on 08 Dec 2018
AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit
3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...
Posted by Michael Wonder on 07 Dec 2018
Underuse of innovative medicines in Germany: A justification for government intervention?
6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse. ...
Posted by Michael Wonder on 15 Nov 2018
German health minister calls for faster adoption of biosimilar drugs
14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...
Posted by Michael Wonder on 07 Nov 2018
Fighting for a streamlined European HTA scheme
6 November 2018 - Anyone wanting a bird’s-eye view of the political operating context for the European pharmaceutical industry need ...
Posted by Michael Wonder on 22 Oct 2018
Pharmaceutical pricing conundrum: time to get rid of it?
21 October 2018 - A basic concept of economics is that a price stems from the intersection between supply and demand ...
Posted by Michael Wonder on 20 Oct 2018
Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
18 October 2018 - The HTA Core Model was developed to improve the transferability of health technology assessment between settings. ...
Posted by Michael Wonder on 10 Oct 2018
New drugs: how much are governments paying for innovation?
10 October 2018 - The medical innovation debate is also heated up due to the ongoing discussion on Health Technology Assessments. ...
Posted by Michael Wonder on 01 Oct 2018
Pertuzumab in early breast cancer: no proof of an additional benefit despite exemplary surrogate validation
1 October 2018 - Effect on disease-free survival too small to conclude on overall survival. ...
Posted by Michael Wonder on 12 Sep 2018
A breakthrough cancer drug has been approved. Now comes the battle over the price.
12 Septemner 2018 - Novartis' breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its ...
Posted by Michael Wonder on 06 Aug 2018
Division on European HTA
3 August 2018 - There have been aspirations for closer collaboration between European Union Member States on health technology assessment for ...
Posted by Michael Wonder on 13 Jul 2018
Getting it right: EPHA recommendations on how to improve the European Commission proposal on health technology assessment
11 July 2018 - The European Public Health Alliance welcomes the European Commission proposal for a regulation on health technology ...
Posted by Michael Wonder on 02 Jul 2018
Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven
2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...
Posted by Michael Wonder on 24 Jun 2018
Industry urges EU to scrap national HTA bodies
22 June 2018 - The pharma industry has called for European member states’ national drug value assessment bodies to be ...